Skip to main content
Back to Sequoia Capital

Sequoia Capital's Pharmaceutical Portfolio

Browse 8 Pharmaceutical companies funded by Sequoia Capital. See funding amounts, founder contacts, and investment details.

Pharmaceutical Companies
8
Total Funding in Pharmaceutical
$1.5B

Pharmaceutical Portfolio Companies (8)

Export
BiotechnologyManufacturingPharmaceutical

GondolaBio researches, develops and manufactures pharmaceutical products.

Palo Alto, United States
August 2024
$300.0M
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyClinical TrialsHealth CareMedicalPharmaceutical

Formation Bio is a drug development company that strives to provide treatments to patients faster by reimagining clinical trials.

New York, United States
June 2024
$372.0M
Series D

Founder Contacts

30,000+ verified contacts

Health CareMedicalMobilePharmaceutical

Nimble provides a pharmacy experience centered around the patient's needs to provide a more streamlined workflow.

Redwood City, United States
June 2022
Venture - Series Unknown

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics

Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.

South San Francisco, United States
May 2026
$115.0M
Post-IPO Equity

Founder Contacts

30,000+ verified contacts

Artificial Intelligence (AI)BiotechnologyHealth CarePharmaceutical

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

Cambridge, United States
March 2025
$123.0M
Series E

Founder Contacts

30,000+ verified contacts

BiotechnologyGeneticsPharmaceuticalTherapeutics

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

South San Francisco, United States
January 2024
$24.0M
Series A

Founder Contacts

30,000+ verified contacts

BiotechnologyHealth CareLife ScienceMedicalPharmaceutical

BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.

Palo Alto, United States
January 2026
$550.0M
Post-IPO Debt

Founder Contacts

30,000+ verified contacts

Artificial Intelligence (AI)BiopharmaBiotechnologyGeneticsNanotechnologyPharmaceuticalTherapeutics

BreezeBio is a biotechnology business that creates genetic therapies using precision, non-viral delivery across clinically important tissues

Brisbane, United States
February 2026
$60.0M
Series B

Founder Contacts

30,000+ verified contacts

Explore Sequoia Capital's Full Portfolio

View all companies funded by Sequoia Capital across every industry and funding stage.

View Full Sequoia Capital Portfolio